Date:8/10/2009

========= =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $6,916,901 $512,382 Accrued expenses 4,415,231 2,898,417 --------- --------- Total current liabilities 11,332,132 3,410,799 Long-term liabilities: Deferred rent 504,811 502,770 ------- ------- Total liabilities 11,836,943 3,913,569 ---------- --------- Stockholders' equity: Common stock 27,140 26,653 Additional paid-in capital 277,149,879 270,988,157 Accumulated other comprehensive income (loss) 213 (20,029) Deficit accumulated during the development stage (243,870,595) (224,974,507) ------------ ------------ Total stockholders' equity 33,306,637 46,020,274 ---------- ---------- Total liabilities and ----------- ----------- stockholders' equity $45,143,580 $49,933,843 =========== =========== VANDA PHARMACEUTICALS INC. (A Development Stage Enterprise) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Six Months Ended ---------------- June 30, June 3
'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
10. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes